Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026. The company presentation is scheduled for 11:30 a.m. ET on January 29, 2026. FibroBiologics is a clinical-stage biotechnology company focused on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending. Management will be available for one-on-one investor meetings during the event and provided contact details for further information.
FibroBiologics (Nasdaq: FBLG) outlined 2025 progress across clinical, manufacturing, IP, corporate and financing milestones.
Key items: opened a >10,000 sq ft Houston lab for discovery and in-house manufacturing; completed FDA cGMP master and working cell banks for CYWC628; received HREC approval in Australia for a 120-patient Phase 1/2 CYWC628 diabetic foot ulcer trial starting Q1 2026 with interim results potentially mid-2026 and topline before end-2026; filed an IND for CYPS317 on Dec 30, 2025; advanced remyelination and bone marrow organoid preclinical data; portfolio exceeds 270 issued and pending patents.
Financing: multiple registered direct offerings in Nov–Dec 2025 including $4M, $1.5M, $1.7M, closed two tranches of a $25M financing by Q2, and paid off all outstanding debt.
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026 in San Francisco.
The company presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026 at The St. Regis. Interested parties may visit the company website or contact info@fibrobiologics.com for more information.
FibroBiologics (Nasdaq: FBLG) reported positive preclinical results for an investigational FSdC spheroid therapy in animal models of degenerative disc disease dated January 5, 2026. Key findings at 12 weeks showed the highest intervertebral disc height recovery versus 2D fibroblasts and fibroblast spheroids, with an unadjusted p-value of 0.00015 for FSdC (compared with 0.036 and 0.068 for comparators).
The study showed sustained highest average disc size index (%DHI) across six measurement periods over 12 weeks. The company says it will pursue regulatory engagement and advance FSdC toward clinical development.
FibroBiologics (Nasdaq: FBLG) filed a Phase 1/2 IND application with the U.S. FDA on Dec 31, 2025 to seek clearance to start first-in-human trials of CYPS317, an allogeneic fibroblast spheroid therapy for moderate to severe psoriasis.
The submission includes preclinical pharmacology, safety, and manufacturing data; animal studies showed a single dose of CYPS317 matched or exceeded multiple doses of anti-IL-23 antibodies and reduced disease recurrence. The company says it aims to advance clinical development and pursue IND clearance for all four product candidates in 2026.
FibroBiologics (Nasdaq: FBLG) announced on Dec 16, 2025 the closing of a registered direct offering of 5,227,275 shares at $0.33 per share and a concurrent private placement of unregistered warrants to purchase up to 5,227,275 shares at an exercise price of $0.33. Aggregate gross proceeds were approximately $1.7 million, before placement agent fees and expenses; potential additional gross proceeds from full warrant exercise are approximately $1.7 million. Warrants become exercisable only after company stockholder approval and expire five years after such approval. Net proceeds will be used for working capital and general corporate purposes.
FibroBiologics (Nasdaq: FBLG) announced a registered direct offering of 5,227,275 shares at $0.33 per share and a concurrent private placement of unregistered warrants exercisable into up to 5,227,275 shares at $0.33. Gross proceeds from the registered offering are expected to be approximately $1.7 million, before fees and expenses, with potential additional proceeds of ~$1.7 million if warrants are fully exercised on a cash basis. Closing is expected on or about December 16, 2025, subject to customary conditions and stockholder approval for warrant exercise shares. H.C. Wainwright is sole placement agent. Proceeds are intended for working capital and general corporate purposes. The registered shares are offered under an effective Form S-3 registration statement.
FibroBiologics (Nasdaq: FBLG) on December 10, 2025 filed a U.S. patent application titled “Spheroids For Cartilage Repair” for a proprietary fibroblast-derived therapy platform targeting orthopedic and musculoskeletal conditions.
The filing seeks protection for use of fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids in degenerative disc repair, cartilage repair, and joint restoration. The company noted preclinical studies showing integration with native tissue, extracellular matrix remodeling, and regeneration in disc and joint degeneration models. FibroBiologics reported a portfolio of 270+ patents issued and pending. The company said the patent, if granted, would broaden protection across multiple orthopedic indications.
FibroBiologics (Nasdaq: FBLG) announced it has paid in full the convertible promissory notes issued to Yorkville under the Standby Equity Purchase Agreement (SEPA), eliminating those notes and any further conversions from those tranches.
The SEPA remains in place through December 20, 2026, allowing the company to sell up to an additional $10 million of common stock to Yorkville, subject to customary conditions. Management said the payoff strengthens the balance sheet and supports plans to initiate a Phase 1/2 trial of CYWC628 in early 2026, and to prepare IND submissions for CYPS317 and CYMS101.
FibroBiologics (Nasdaq: FBLG) closed a registered direct offering of 4,477,614 common shares at $0.335 per share for aggregate gross proceeds of approximately $1.5 million on Nov 25, 2025.
In a concurrent private placement the company issued unregistered warrants to purchase up to 4,477,614 shares at an exercise price of $0.335; exercise and sale of shares from those warrants require shareholder approval and, if fully exercised for cash, would generate approximately $1.5 million.
H.C. Wainwright served as exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes.